(19)
(11) EP 2 243 474 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.03.2015 Bulletin 2015/11

(45) Mention of the grant of the patent:
21.01.2015 Bulletin 2015/04

(21) Application number: 09005726.6

(22) Date of filing: 23.04.2009
(51) International Patent Classification (IPC): 
A61K 31/122(2006.01)
 A61P 31/00(2006.01)

(54)

Protective effect of thymoquinone in sepsis

Schutzwirkung von Thymoquinon in Sepsis

Effet prospecteur de thymoquinone dans la sepsie

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(43) Date of publication of application:
27.10.2010 Bulletin 2010/43

(73) Proprietor: King Saud University
11421 Riyadh (SA)

(72) Inventors:
  • Alkharfy, Khalid
    Riyadh 11451 (SA)
  • Al-Daghri, Nasser M.
    Riyadh 11451 (SA)
  • Al-Attas, Omar S.
    Riyadh 11451 (SA)
  • Alokail, Majed S.
    Riyadh 11653 (SA)

(74) Representative: Engelhard, Markus 
Boehmert & Boehmert Anwaltspartnerschaft mbB Patentanwälte Rechtsanwälte Pettenkoferstrasse 20-22
80336 München
80336 München (DE)


(56) References cited: : 
WO-A-2006/024545
 US-A1- 2003 060 454
   
  • EL GAZZAR ET AL: "Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation" BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1770, no. 4, 22 February 2007 (2007-02-22), pages 556-564, XP005900229 ISSN: 0304-4165
  • ALSAIF M A: "Effect of Nigella sativa oil in metabolic responsed to prolonged systemic injury in rats" JOURNAL OF BIOLOGICAL SCIENCES 2008 PK, vol. 8, no. 6, 2008, pages 974-983, XP009118155 ISSN: 1727-3048 1812-5719
  • YILDIZ FAHRETTIN ET AL: "Nigella sativa relieves the deleterious effects of ischemia reperfusion injury on liver." WORLD JOURNAL OF GASTROENTEROLOGY : WJG 7 SEP 2008, vol. 14, no. 33, 7 September 2008 (2008-09-07), pages 5204-5209, XP002531818 ISSN: 1007-9327
  • EL GAZZAR M A: "Thymoquinone suppressses in vitro production of IL-5 and IL-13 by mast cells in response to lipopolysaccharide stimulation" INFLAMMATION RESEARCH ; OFFICIAL JOURNAL OF: THE INTERNATIONAL ASSOCIATION OF INFLAMMATION SOCIETIES THE EUROPEAN HISTAMINE RESEARCH SOCIETY, BIRKHÄUSER-VERLAG, BA, vol. 56, no. 8, 1 August 2007 (2007-08-01), pages 345-351, XP019531449 ISSN: 1420-908X
  • LIU M ET AL: "GROWTH-INHIBITING ACTIVITY OF ANTHRAQUINONES AND BENZOQUINONES AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)" DOKKYO JOURNAL OF MEDICAL SCIENCES, MIBU, JP, vol. 23, no. 2, 1 January 1996 (1996-01-01), pages 85-93, XP000908978 ISSN: 0385-5023
  • LAI P K ET AL: "Antimicrobial and chemopreventive properties of herbs and spices" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 11, no. 11, 1 June 2004 (2004-06-01), pages 1451-1460, XP009117713 ISSN: 0929-8673
  • ALJABRE S H M ET AL: "Antidermatophyte activity of ether extract of Nigella sativa and its active principle, thymoquinone" JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 101, no. 1-3, 3 October 2005 (2005-10-03), pages 116-119, XP025270010 ISSN: 0378-8741 [retrieved on 2005-10-03]
  • SHIGEHARU INOUYE ET AL: "Evaluation of the effect of terpenoid quinones on Trichophyton mentagrophytes by solution and vapor contact" JOURNAL OF INFECTION AND CHEMOTHERAPY ; OFFICIAL JOURNAL OF THE JAPANESE SOCIETY OF CHEMOTHERAPY AND THE JAPANESE ASSOCIATION FORINFECTIOUS DISEASES, SPRINGER-VERLAG, TO, vol. 12, no. 2, 1 April 2006 (2006-04-01), pages 100-104, XP019374935 ISSN: 1437-7780
  • EL-DAKHAKHNY MOHAMED ET AL: "Protective effect of Nigella sativa oil and clindamycin against production of tumor necrosis factor-alpha and liver injury in murine septic peritonitis" NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 362, no. 4-5 Supplement, 2000, page R17, XP009118158 & ANPT-SYMPOSIUM; BERLIN-DAHLEM, GERMANY; SEPTEMBER 27, 2000 ISSN: 0028-1298
  • ALI B H ET AL: "Pharmacological and toxicological properties of Nigella sativa", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 17, no. 4, 1 January 2003 (2003-01-01), pages 299-305, XP002538026, ISSN: 0951-418X, DOI: 10.1002/PTR.1309
  • COHEN J ET AL: "INTERSEPT: AN INTERNATIONAL, MULTICENTER, PLACEBO-CONTROLLED TRIAL OF MONOCLONAL ANTIBODY TO HUMAN TUMOR NECROSIS FACTOR-ALPHA PATIENTS WITH SEPSIS", CRITICAL CARE MEDICINE,, vol. 24, no. 9, 1 September 1996 (1996-09-01), pages 1431-1440, XP000655200, ISSN: 0090-3493, DOI: 10.1097/00003246-199609000-00002
  • ABRAHAM E ET AL: "Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 351, no. 9107, 8 March 1998 (1998-03-08), pages 929-933, XP004266935, ISSN: 0140-6736
  • DHAINAUT J F ET AL: "CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group", CRITICAL CARE MEDICINE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 23, no. 9, 1 September 1995 (1995-09-01), pages 1461-1469, XP009178281, ISSN: 0090-3493
  • Charles J. Fisher ET AL: "Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein", New England Journal of Medicine, vol. 334, no. 26, 27 June 1996 (1996-06-27), pages 1697-1702, XP055121181, ISSN: 0028-4793, DOI: 10.1056/NEJM199606273342603
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).